Ultragenyx Sets 2027 Expense Targets as It Winds Down GTX-102

Ultragenyx Pharmaceutical Inc. set lower expense targets for 2027 while reaffirming its forecast for full-year GAAP profitability, tying the plan to a roughly 20% workforce reduction and the wind-down of GTX-102 studies. The company announced Tuesday, Nov. 3, that it expects full-year research and development expenses below $350 million and selling, general and administrative expenses below $375 million in 2027. The R&D target is at least 50% below 2025 levels. Ultragenyx develops and commercializes treatments for rare and ultra-rare genetic diseases.

Source: TokenPost